Milestone Scientific Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $9.4M+9.2% YoYTTM through 30 Jun 2026
Net Income -$4.1MTTM through 30 Jun 2026
Free Cash Flow -$657.8KTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 71.1% |
| EBITDA Margin | -42.7% |
| Operating Margin | -63.3% |
| Net Margin | -44.0% |
Returns
-202.7%ROE
-73.0%ROA
Balance Sheet Health
Debt / Equity0.28x
Current Ratio1.81x
Net Debt-$300Knet cash position
Cash & Equivalents$1.2M
Quality Metrics
Altman Z-Score-18.28
Piotroski F-Score4 / 9
FCF Margin-7.0%
Rule of 40-1.1
Earnings-Beat Rate50.0%
Multi-Year Trend
RevenueFY2025: $9M
Diluted EPS-$0.05TTMFY2025: $-0.07
Dividend
No dividend
Capital Allocation
R&D Spend$35.2K
Capex Intensity0.2%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Dental | View detailsFocusing on domestic expansion through the Dental Ambassador Program launched as a pilot in December 2025. | ||
| Medical | View detailsManagement expects CompuFlo revenue to reach $500,000 to $600,000 in 2026, representing an approximately 400% increase over 2025. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.